The target of Tivozanib

Tivozanib is designed to target the vascular endothelial growth factor (VEGF) pathway, a clinically proven target in renal cell carcinoma. Tivozanibis a TKI for VEGFR-1, 2 and 3. It is a very effective and selective tyrosine kinase inhibitor. In vitro cellular kinase assays demonstrated that tivozanib inhibits the phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3 at clinically relevant concentrations, and inhibits other kinases, including c-kit and PDGFR beta. Tivozanib inhibited angiogenesis, vascular permeability, and tumor growth in various tumor cell types, including human renal cell carcinoma, in mouse and rat tumor xenograft models.